Elekta: New Data on Stereotactic Neurosurgery Devices Presented at AANS

Monday, April 24, 2017

Elekta's Leksell Gamma Knife® radiosurgery system has been highlighted in more than 15 scientific presentations at the American Association of Neurological Surgeons (AANS) Annual Meeting in Los Angeles, the company reports. 

"Stereotactic Radiosurgery for Intractable Tremor-Dominant Parkinson Disease" reports a study that analyzed the outcomes of 33 patients who received Gamma Knife radiosurgery to treat medically refractory Parkinson's disease (PD) tremor. At a mean follow-up period of 23 months, 23 patients (70.0 percent) had complete or nearly complete tremor arrest and nine (27.2 percent) experienced tremor arrest and improved ability to write, draw and drink fluids. Tremor resolution was maintained in 96.8 percent of individuals at last follow-up visit. Study investigators concluded that Gamma Knife is a safe and effective treatment for medically refractory PD tremor, especially in the elderly or individuals who are not suitable candidates for deep brain stimulation or thermal therapy.

"Direct Comparison of Microsurgery and Gamma Knife Radiosurgery on Small Size Meningiomas" reports a retrospective review of 90 consecutive patients with small intracranial meningiomas (benign tumors arising from the membranes covering the brain and spinal cord) undergoing microsurgery (n= 31) or Gamma Knife radiosurgery (n=59). Study results demonstrated that Gamma Knife radiosurgery was associated with significantly higher local control of tumor growth compared with microsurgical resection at five and 10 years (p=0.02 and p=0.003, respectively). In addition, the median recurrence free survival period was also significantly higher in the Gamma Knife group (p=0.04).

Elekta also reports that its Leksell®Vantage™ Stereotactic System*, which received CE Mark clearance in March 2017, will be used this month in clinical practice for the first time in Europe at University Hospital La Timone (Marseilles, France), The Academic Medical Center (Amsterdam, the Netherlands), The National Hospital for Neurology and Neurosurgery, Queens Square (London, England) and Karolinska University Hospital (Stockholm, Sweden). The system is currently pending 510(k) clearance with the U.S. Food and Drug Administration.

Next Story


You must be logged in to leave a comment.